

# Membership in Association of the Pharmaceutical Industry in Norway (LMI)

*Membership in LMI provides better insight into the pharmaceutical industry on a national and international scale. It provides member companies with greater opportunity to influence central processes related to pharmaceuticals and encourages professional participation in our committees and councils – and offer advice on everything from regulatory processes to health policy.*

*Membership is open to Norwegian and foreign pharmaceutical companies that develop, produce, sell or market medications and pharmacological substances in and for Norway. LMI has 66 member companies.*

*The association aims to protect the professional interests of its members where the pharmaceutical industry is concerned. Good framework agreements will provide Norwegian patients with access to safe essential medications to improve the health, well-being and quality of life for the Norwegian population. LMI plays a key political role in setting policies regarding the industry and also contributes by making the pharmaceutical industry's contributions and achievement visible within the community.*

## **WHY BECOME A MEMBER OF LMI?**

### **Influence**

LMI is an innovative trade organization that tries to influence commercial, nutritional and health policies and national visions on behalf of its member companies. By participating in our community, your voice will be heard on issues of importance to our trade and you can help LMI influence decisions made by the authorities and by other relevant operators in the trade.

### **Access**

We have many channels to help our members have a say in matters of importance: General meetings and strategy sessions, trade seminars, meetings directed at specific topics and current themes and GM meetings, where you can meet people with similar interests, challenges and experiences. LMI works hard to facilitate the exchange of information and experience between our member companies.

### **Participation**

The employees of LMI member companies are also given the opportunity to participate in various working groups and committees that provide advice to trade organizations and offer guidance for the work done by these organizations. This allows you to help LMI decide which issues are put on the agenda and provides members with insight and knowledge about important processes within the health industry.

## **Insight**

Our extranet, Digitalis, and our daily newsletters provide our members with access to the most important news and information from the pharmaceutical industry, nationally and internationally.

These channels of information include articles, meeting notes and summaries from Norwegian and European pharmaceutical authorities, information from the European Federation of Pharmaceutical Industries and Associations (EFPIA), important meetings and conferences as well as other essential information about and from the pharmaceutical industry.

**You will also have access to LMI's communications team.**

## **Network**

LMI has an extensive network in academic, political, financial and regulatory environments.

LMI is also a part of the Confederation of Norwegian Business and Industry (NHO) through its membership in NHO Geneo. All members of LMI become members of NHO automatically and benefit from an extended network - within Norwegian industrial environments in particular and commercial environments in general.

## **Advantages**

As a member of NHO, you also have access to unlimited expertise and many other benefits. This includes legal advice regarding employment law and more affordable legal services, advice and assistance on public procurement, various economic benefits such as taking part in NHO's Service Pension and other insurance schemes, hotel deals etc. [You get this as a member of NHO](#)

## **What does membership cost?**

The membership fee consists of fixed fees and a part based on earnings. Companies with lower earnings and companies that mainly work to develop drugs that they are still not permitted to market and thus have no income from the sale of such pharmaceuticals may be granted a lower membership fee.